Grant Publications

Proposal No. IBD-0226R
Principal Investigator: Shanthi V. Sitaraman, M.D., Ph.D.
Applicant Organization: Emory University (Atlanta, Georgia, U.S.A.)
Project Title: Prohibitin: a novel antioxidant based treatment for inflammatory bowel disease
Period of Award: January 1, 2009 – March 31, 2010

Theiss AL, Jenkins AK, Okoro NI, Klapproth JM, Merlin D, Sitaraman SV.  Prohibitin inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via the novel mechanism of decreasing importin alpha3 expression.  Molecular Biology of the Cell 2009;20:4412-4423.

Theiss AL, Vijay-Kumar M, Obertone TS, Jones DP, Hansen JM, Gewirtz AT, Merlin D, Sitaraman SV.  Prohibitin is a novel regulator of antioxidant response that attenuates colonic inflammation in mice.  Gastroenterology 2009;137:199-208.

Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, Merlin D, Sitaraman SV.  Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis.  Inflammatory Bowel Diseases 2011;17:1163-76.